Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Sihuan Pharmaceutical Holdings Group Ltd. has announced the market purchase of 5 million shares as part of its 2022 Share Award Scheme, representing approximately 0.05% of the total shares in issue. With a focus on the medical aesthetics and biopharmaceutical sectors, Sihuan Pharmaceutical aims to strengthen its position as a leading company in China. The share acquisition, executed at an average price of HK$0.5580 per share, aligns with the company’s strategic objectives and ongoing commitment to innovation and growth.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
